ABBV
AbbVie Inc.
ABBV
AbbVie Inc.
NORTH CHICAGO, Ill., Sept. 10, 2026 /PRNewswire/ -- The board of directors of AbbVie Inc. (NYSE: ABBV) today declared a quarterly cash dividend of $1.73 per share.
Great Lakes Advisors LLC bought a new stake in AbbVie Inc. (NYSE: ABBV) during the second quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commissi
Danske Bank A S acquired a new position in AbbVie Inc. (NYSE: ABBV) in the undefined quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm acquired 1,3
Compass Wealth Management LLC purchased a new stake in shares of AbbVie Inc. (NYSE: ABBV) during the second quarter, according to the company in its most recent 13F filing with the SEC. The institutio
Danica Pension Livsforsikringsaktieselskab acquired a new position in shares of AbbVie Inc. (NYSE: ABBV) in the undefined quarter, according to its most recent filing with the Securities and Exchange
Submission supported by data from Phase 3 pivotal AFFIRM study If approved, adult Crohn's disease patients will have an additional option for induction of risankizumab which is already approved for in
Ironwood Pharmaceuticals is a small-cap GI-focused biotech with strong LINZESS sales but looming patent expiry by 2029–2030. IRWD raised LINZESS full-year U.S. net sales guidance to $1.15–$1.2 billion
Clinical data from AbbVie's ABBV-1480 (RC148) PD-1/VEGF bispecific antibody in the frontline non-small cell lung cancer (NSCLC) setting will be presented via an oral presentation Additionally, new dat
AbbVie Inc. (ABBV) Q2 2026 Earnings Call Transcript
AbbVie NYSE: ABBV reported second-quarter 2026 results that exceeded its expectations, supported by double-digit growth in its immunology and neuroscience businesses, and raised its full-year revenue
Reports Second-Quarter Diluted EPS of $2.03 on a GAAP Basis, an Increase of 290.4 Percent; Adjusted Diluted EPS of $3.65, an Increase of 22.9 Percent; These Results Include an Unfavorable Impact of $0
RINVOQ ® is now approved in the European Union for the treatment of adult and adolescent patients with severe alopecia areata (AA) Approval was based on the pivotal Phase 3 UP-AA clinical program, whi
RINVOQ is the first and only systemic medication approved in the European Union to treat adult and adolescent patients with non-segmental vitiligo (NSV) The approval is supported by data from the Phas
Wall Street faces one of its busiest weeks of the summer, with earnings from four of the Magnificent Seven companies, the Federal Reserve's latest policy decision, and key inflation data all set to te
Eli Lilly and Company, Abbott Laboratories, AbbVie, Novo Nordisk A/S, Pfizer, Bristol Myers Squibb, and Gilead Sciences are the seven Pharmaceutical stocks to watch today, according to MarketBeat's st
AbbVie earns a buy rating, supported by accelerating top and bottom-line growth and a compelling valuation at 18x forward P/E. ABBV offers a 2.7% forward dividend yield, outperforming peers by 68%, an
Boey® is the first and only rapid-onset and short-duration botulinum neurotoxin serotype E approved in Europe that adult patients can try for the temporary improvement of glabellar lines¹ Results may
Big Pharma has a $300 billion problem, and biotech developers with promising drugs are becoming the fix. Major drugmakers are spending at a pace not seen since 2019 to replace medicines that will soon
AbbVie is acquiring Apogee Therapeutics for $10.9B, reinforcing its immunology franchise and addressing future patent cliffs proactively. Skyrizi and Rinvoq have already replaced Humira's revenue, wit